Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: A concern about the metabolism of artemisinin-based combinations

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Marwa, Karol J ^a   Schmidt, Theresa ^b   Sjögren, Maria ^b   Minzi, Omary M S ^c   Kamugisha, Erasmus ^a   Swedberg, Göte ^b  

^a CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b UPPSALA UNIVERSITY   (Sweden)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

Artemisinin based combination therapy; Cytochrome P450; Plasmodium falciparum malaria; Poor metabolizers; Tanzania

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CYTOCHROME P450;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYP2B6 GENE; CYP2C8 GENE; CYP3A4 GENE; CYP3A5 GENE; DRUG METABOLISM; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; INDIGENOUS PEOPLE; MALARIA FALCIPARUM; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TANZANIAN; GENETICS; MALARIA; TANZANIA; YOUNG ADULT;

ADULT; ANTIMALARIALS; ARTEMISININS; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; HUMANS; MALARIA; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TANZANIA; YOUNG ADULT;

EID: 84920829535     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-420     Document Type: Article

References (61)

1. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH, Schwab M: Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009, 9:760-774.
2. Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal-Okeng JW, Gordi T, Jerling M: Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol 2008, 65:493-501.
3. Arav-Boger R, Shapiro TA: Molecular mechanisms of resistance in antimalarial chemotherapy: The unmet challenge. Annu Rev Pharmacol Toxicol 2005, 45:565-585.
4. Shah RR: Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci 2005, 360:1617-1638.
5. Seripa D, Pilotto A, Panza F, Matera MG: Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev 2010, 9:457-474.
6. Bains RK: African variation at cytochrome P450 genes evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health 2013, 2013:118-134.
7. Guengerich FP: Cytochrome P450s and other enzymes in drug metabolism and toxicity. Aaps J 2006, 8:E101-E111.
8. Lynch T, Price A: The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007, 76:391-396.
9. Ingelman-Sundberg M, Oscarson M, McLellan RA: Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 1999, 20:342-349.
10. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001, 52:349-355.
11. Miners JO, Birkett DJ: Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998, 45:525-538.
12. Finta C, Zaphiropoulos PG: The human CYP2C locus: A prototype for intergenic and exon repetition splicing events. Genomics 2000, 63:433-438.
13. Totah RA, Rettie AE: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005, 77:341-352.
14. Daily EB, Aquilante CL: Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies. Pharmacogenomics 2009, 10:1489-1510.
15. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF: Structure of human microsomal cytochrome P450 2C8: evidence for a peripheral fatty acid binding site. J Biol Chem 2004, 279:9497-9503.
16. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF: Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 2008, 283:17227-17237.
17. Naraharisetti SB, Lin YS, Rieder MJ, Marciante KD, Psaty BM, Thummel KE, Totah RA: Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos 2010, 38:889-893.
18. Hoffman SM, Nelson DR, Keeney DS: Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001, 11:687-698.
19. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M: Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007, 8:743-759.
20. Wang H, Tompkins LM: CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008, 9:598.
21. King J, Aberg JA: Clinical impact of patient population differences and genomic variation in efavirenz therapy. Aids 2008, 22:1709-1717.
22. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM: Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005, 15:861-873.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270:414-423.
24. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998, 38:389-430.
25. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
26. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002, 54:1271-1294.
27. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR: Increased transcriptional activity of the CYP3A4 1B promoter variant. Environ Mol Mutagen 2003, 42:299-305.
28. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T: Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993, 218:585-595.
29. Staehli Hodel EM, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, Decosterd LA, Olliaro P, Beck HP, Genton B: Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-Acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother 2013, 57:950-958.
30. Piedade R, Gil JP: The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol 2011, 7:1185-1200.
31. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M: Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005, 338:299-305.
32. Temesvari M, Kobori L, Paulik J, Sarvary E, Belic A, Monostory K: Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 2012, 341:294-305.
33. Zhou SF, Liu JP, Chowbay B: Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009, 41:89-295.
34. Alessandrini M, Asfaha S, Dodgen TM, Warnich L, Pepper MS: Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 2013, 45:253-275.
35. Hodel EM, Ley SD, Qi W, Ariey F, Genton B, Beck HP: A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs. Malar J 2009, 8:285.
36. Paganotti GM, Gramolelli S, Tabacchi F, Russo G, Modiano D, Coluzzi M, Romano R: Distribution of human CYP2C8 2 allele in three different African populations. Malar J 2012, 11:125.
37. Rodriguez S, Gaunt TR, Day IN: Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009, 169:505-514.
38. Zeigler-Johnson C, Walker A, Mancke B, Spangler E, Jalloh M, McBride S, Deitz A, Malkowicz S, Ofori-Adjei D, Gueye S: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002, 54:13-21.
39. Swart M, Skelton M, Wonkam A, Kannemeyer L, Dandara C: CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two Bantuspeaking populations from Cameroon and South Africa: implications for global pharmacogenetics. Curr Pharmacogenomics Personalized Med 2012, 10:43-53.
40. Bains RK, Kovacevic M, Plaster CA, Tarekegn A, Bekele E, Bradman NN, Thomas MG: Molecular diversity and population structure at the cytochrome P450 3A5 gene in Africa. BMC Genet 2013, 14:1-18.
41. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M: Genetic variants in CYP (-1A2,-2C9,-2C19,-3A4 and-3A5), VKORC1 and ABCB1 genes in a black South African population: A window into diversity. Pharmacogenomics 2011, 12:1663-1670.
42. Drogemoller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D, Koen L, Gebhardt S, Schneider N, Olckers A, Wright G, Warnich L: Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet 2013, 4:17.
43. Kudzi W, Dodoo AN, Mills JJ: Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: A plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010, 11:111.
44. Oliveira E, Pereira R, Amorim A, McLeod H, Prata MJ: Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics 2009, 10:1413-1422.
45. Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, Ali AS, Bhattarai A, Ribeiro V, Bjorkman A, Gil JP: Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 2008, 30:10-15.
46. Cavaco I, Reis R, Gil JP, Ribeiro V: CYP3A4 1B and NAT2 14 alleles in a native African population. Clin Chem Lab Med 2003, 41:606-609.
47. Roy J-N, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, Roger M: CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005, 33:884-887.
48. Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S, Di Perri G: Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol 2012, 74:134-140.
49. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL: Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007, 82:197-203.
50. Kudzi W, Dodoo AN, Mills JJ: Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009, 10:124.
51. Adjei GO, Kristensen K, Goka BQ, Hoegberg LC, Alifrangis M, Rodrigues OP, Kurtzhals JA: Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother 2008, 52:4400-4406.
52. Rower S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah RN, Pfutzner A, Mockenhaupt FP: High prevalence of the cytochrome P450 2C8 2 mutation in Northern Ghana. Trop Med Int Health 2005, 10:1271-1273.
53. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C: High prevalence of the CYP2B6 516G→T(6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008, 64:357-365.
54. Arnaldo P, Thompson RE, Lopes MQ, Suffys PN, Santos AR: Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population. Malays J Med Sci 2013, 20:13-23.
55. Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, Bjorkman A, Gil JP: CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol 2005, 61:15-18.
56. Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J: Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 2013, 8:e67946.
57. Parathyras J, Gebhardt S, Hillermann-Rebello R, Grobbelaar N, Venter M, Warnich L: A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 2009, 54:261-265.
58. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, Nzarubara B, Talisuna AO, Kamya MR, Rosenthal PJ, Dorsey G, Staedke SG: Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J 2008, 7:106.
59. Tayeb MT, Clark C, Ameyaw MM, Haites NE, Evans DA, Tariq M, Mobarek A, Ofori-Adjei D, McLeod HL: CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000, 10:753-756.
60. Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013, 138:103-141.
61. Paganotti GM, Cosentino V, Russo G, Tabacchi F, Gramolelli S, Coluzzi M, Romano R: Absence of the human CYP2C8 3 allele in Ugandan children exposed to Plasmodium falciparum malaria. Infect Genet Evol 2014, 27:432-435.